Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics

Lucid Diagnostics has a market cap or net worth of $193.95M. The enterprise value is $95.81M.

Lucid Diagnostics has 203,066,790 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lucid Diagnostics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -135.05%.

The current PE Ratio of Lucid Diagnostics is ―. Lucid Diagnostics’s PEG ratio is 0.06.

In the last 12 months, Lucid Diagnostics had revenue of 4.71M and earned -58.01M in profits. Earnings per share was -0.69.

In the last 12 months, operating cash flow was -46.12M and capital expenditures -319.00K, giving a free cash flow of -46.44M billion.

Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Lucid Diagnostics upcoming earnings date is Aug 17, 2026, After Close (Confirmed).

Lucid Diagnostics as a current ratio of 1.31, with Debt / Equity ratio of 670.08%

In the past 12 months, Lucid Diagnostics has paid 0.00 in taxes.

Lucid Diagnostics EV to EBITDA ratio is -2.10, with an EV/FCF ratio of >-0.01.

Lucid Diagnostics has $27.88M in cash and marketable securities with $26.80M in debt, giving a net cash position of $1.07M billion.

Gross margin is -40.03%, with operating margin of -1054.82%, and net profit margin of -1232.68%.

The average price target for Lucid Diagnostics is $3.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy